Clathrate Therapeutics Platform

The agency is seeking a vendor to provide a clathrate therapeutics platform. This platform represents a novel system for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. The desired technology must target therapeutic gases to the intended site while minimizing systemic exposure and providing sustained, tunable dosing under physiological conditions. The agency requires a platform that improves safety margins by separating therapeutic effects from toxicity risks. The requested system must offer versatility across oncology, cardiovascular, neurological, and regenerative indications. To optimize development, the platform must be supported by predictive modeling to guide dose and design decisions. The agency specifies that the architecture must be partnership-ready and suitable for integration with drug-device combinations and existing treatment modalities. Only onshore organizations based in the United States are eligible to submit proposals. The selected vendor will perform all work offsite. The agency is currently looking for proposals to determine the budget and has not established key dates or specific evaluation criteria in the initial request.